MetaVia said data from its Phase 1 trial of DA-1726 have been accepted for an oral presentation at the Precision Liver Symposium on Nov. 4 in Denver. The announcement is a clinical-data update for the company’s experimental obesity and metabolic-disease drug; it does not report new trial measurements or a development milestone beyond acceptance of the presentation.
The presentation title points to reductions in liver fat and body weight, with relative preservation of lean mass. The detailed results are expected at the symposium.
- What will be presented: The abstract is titled “DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial.” MRI-PDFF is an imaging measure of liver fat.
- Presentation details: MetaVia Chief Medical Officer Sarah Browne will present at 1:35 p.m. Mountain Time at the Hilton Denver City Center. The company said a copy of the poster will be posted on its website after the presentation.
- About DA-1726: The drug is a once-weekly injectable designed to activate both GLP-1 and glucagon receptors. MetaVia says it is developing the treatment for metabolic disease.
- What is not in the announcement: No numerical trial results, dose-by-dose data, or safety findings are provided. The presentation title describes the reported outcomes, but the release does not provide enough detail to assess their size or clinical significance.
- Other pipeline context: MetaVia is also developing vanoglipel, or DA-1241, for metabolic dysfunction-associated steatohepatitis (MASH). The company says the candidate showed liver and glucose-related effects in an earlier Phase 2a study.
The announcement adds a scheduled opportunity to hear more about DA-1726’s clinical data. It does not itself establish the drug’s efficacy or safety; those assessments depend on the detailed trial results.